The treatment landscape in relapsed/refractory chronic lymphocytic leukaemia (CLL) has rapidly evolved over the past five years, with one such emergent treatment being the BCL2 inhibitor, venetoclax. This oral treatment has demonstrated significant clinical advantages in indicated patients, but rapid tumour debulking can lead to a treatment-related risk of the acute condition known as tumour lysis syndrome (TLS). Here, I present real patient cases to show how I have used the recommended predose monitoring and prophylactic procedures to mitigate the risk of TLS. I also used the ramp-up dose escalation schedule of venetoclax therapy initiation to safely take patients through the treatment, successfully providing them with sustained clinical benefits.

中文翻译：

---

接受维奈托克治疗的慢性淋巴细胞白血病患者肿瘤溶解综合征的实际治疗。

复发/难治性慢性淋巴细胞白血病 (CLL) 的治疗格局在过去五年中迅速发展，其中一种新兴治疗方法是 BCL2 抑制剂 Venetoclax。这种口服治疗已在指定患者中表现出显着的临床优势，但快速肿瘤减灭可能会导致与治疗相关的急性疾病风险，即肿瘤溶解综合征（TLS）。在这里，我将介绍真实的患者案例，以展示我如何使用推荐的给药前监测和预防程序来降低 TLS 风险。我还使用维奈托克治疗开始时的剂量递增时间表来安全地引导患者完成治疗，成功地为他们提供持续的临床益处。